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Abstract
Sarcoidosis is a multisystemic disorder of unknown cause characterized by the formation of
immune granulomas in involved organs. It is an ubiquitous disease with incidence (varying according
to age, sex, race and geographic origin) estimated at around 16.5/100,000 in men and 19/100,000
in women. The lung and the lymphatic system are predominantly affected but virtually every organ
may be involved. Other severe manifestations result from cardiac, neurological, ocular, kidney or
laryngeal localizations. In most cases, sarcoidosis is revealed by persistent dry cough, eye or skin
manifestations, peripheral lymph nodes, fatigue, weight loss, fever or night sweats, and erythema
nodosum. Abnormal metabolism of vitamin D3 within granulomatous lesions and hypercalcemia
are possible. Chest radiography is abnormal in about 90% of cases and shows lymphadenopathy
and/or pulmonary infiltrates (without or with fibrosis), defining sarcoidosis stages from I to IV. The
etiology remains unknown but the prevailing hypothesis is that various unidentified, likely poorly
degradable antigens of either infectious or environmental origin could trigger an exaggerated
immune reaction in genetically susceptible hosts. Diagnosis relies on compatible clinical and
radiographic manifestations, evidence of non-caseating granulomas obtained by biopsy through
tracheobronchial endoscopy or at other sites, and exclusion of all other granulomatous diseases.
The evolution and severity of sarcoidosis are highly variable. Mortality is estimated at between 0.5–
5%. In most benign cases (spontaneous resolution within 24–36 months), no treatment is required
but a regular follow-up until recovery is necessary. In more serious cases, a medical treatment has
to be prescribed either initially or at some point during follow-up according to clinical
manifestations and their evolution. Systemic corticosteroids are the mainstay of treatment of
sarcoidosis. The minimal duration of treatment is 12 months. Some patients experience repeated
relapses and may require long-term low-dose corticosteroid therapy during years. Other
treatments (immunosuppressive drugs and aminoquinolins) may be useful in case of unsatisfactory
response to corticosteroids, poor tolerance and as sparing agents when high doses of
corticosteroids are needed for a long time. In some strictly selected cases refractory to standard
therapy, specific antiTNF-α agents may offer precious improvement. Some patients benefit from
topical corticosteroids.
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Sarcoidosis is a multisystemic disorder of unknown cause
that is characterized by the formation of immune granu-
lomas in involved organs [1-4].
Background
Sarcoidosis affects primarily young and middle-aged
adults. A prevailing hypothesis is that various unidentified
antigens, either infectious or environnemental, could trig-
ger an exaggerated immune reaction in genetically suscep-
tible hosts [2]. The clinical expression of sarcoidosis is
protean, in particular as regards the number and sites of
involved organs. The lung and the lymphatic system are
predominantly affected but virtually virtually every organ
may be affected. Skin, eyes, peripheral lymph nodes and
liver are each involved in 10–25% of cases. The evolution
and severity of the disease are highly variable. Whilst
spontaneous resolution occurs in the majority of cases
within 12–36 months, some patients experience a pro-
longed and serious course [3]. Pulmonary fibrosis is the
most frequent severe manifestation, accounting for the
major cause of morbidity and mortality in western coun-
tries [3]. Other severe manifestations of the disease consist
of cardiac, neurological, ocular, kidney or laryngeal local-
izations. Sarcoidosis can also induce abnormal metabo-
lism of vitamin D3 within granulomatous lesions and
hypercalcemia [5]. Mortality attributable to sarcoidosis is
estimated at between 0.5 and 5% [6] and results from
lung, heart and central nervous system localizations [3].
Although not always required, the mainstay of sarcoidosis
treatment is systemic corticosteroids [7,8]. Corticosteroids
impeed the formation of granulomas and, as a result, are
largely efficient against most active clinical manifesta-
tions. However, treatment is merely suspensive with fre-
quent relapses when withdrawal is too rapid.
Furthermore, the adverse side effects of corticosteroids are
substantial. Other immunosuppressive agents and amino-
quinolins can be employed as sparing drugs or as alterna-
tive options to corticosteroid therapy in patients with
unsatisfactory response or poor tolerance with corticoster-
oids, or when high doses of corticosteroids are needed for
a long time [8]. Recent advances on the knowledge of sar-
coidosis pathogeny suggest that the overproduction of
tumor necrosis factor α (TNF-α) at the sites of disease
plays a pivotal role [2]. Interstingly, most agents that are
effective in sarcoidosis also appear to have antiTNF-α
properties, either specifically or as part of broad effects [4].
Epidemiology
Sarcoidosis is an ubiquitary disease with an incidence var-
ying according to age, sex, race and geographic origin
[1,3,4,9]. Sarcoidosis incidence is globally estimated at
around 16.5/100,000 in men and 19/100,000 in women
[10]. The lifetime incidence is higher in women (1.3%)
than in men (1%), and in Blacks (2.4%) than in Cauca-
sians (0.8%) [10,11]. Although possible at all ages, a pre-
dilection is observed between 25 and 40 years in both
genders at least in Scandinavian countries and Japan
[3,10], and a second peak of incidence has been reported
in women over 50 years of age in some but not all pub-
lished series [10]. The incidence of sarcoidosis is remark-
ably low before 15 years (1/100,000) and exceptional
before 4 years (0.06/100,000) [12]. The clinical expres-
sion and severity of sarcoidosis depend upon epidemio-
logical factors. Erythema nodosum is seen in 3–44% of
cases but it is far more frequent in women than in men, in
Caucasians than in Blacks or in Japanese and in northern
than in southern european countries [1,3,12]. In Blacks,
the disease is more likely to be disseminated, showing a
higher frequency of ophtalmological, cutaneous, hepatic
and lymphatic localizations [9] and it is undeniably more
severe [3]. In Japanese patients, cardiac and ophthalmo-
logical involvement is common [3]. Sarcoidosis is gener-
ally sporadic but a familial aggregation is found in 1.7–
17% of cases [12,13]. The risk of sarcoidosis is increased
in the family of an index case with siblings having the
highest relative risk (odd ratio = 5.8) [13]. Interestingly,
there are strands of evidence provided by familial sar-
coidosis supporting the role of genetic factors: the similar-
ity of phenotypical presentation among families, the
similarity of the mother/children and father/children
ratios, and the higher incidence and phenotypical resem-
blance between homozygotic twins than between hetero-
zygotic twins.
Time and space-related clusters, tracing case contacts and
cases of possible transmission of sarcoidosis via transplan-
tation all suggest the role of transmissible agents either of
infectious or of environnemental origin, although not
identified yet [14].
Cause and mechanism of sarcoidosis
Sarcoidosis is considered as the consequence of a chronic
immunological response associating a genetic susceptibil-
ity and specific infectious or environmental factors [15-
17]. Sarcoid granuloma, the typical elementary micro-
scopical lesion, is an immune granuloma resulting from a
specific cell-mediated immune response to a likely poorly
degradable antigenic agent. Numerous cytokines and
other mediators are produced by both activated macro-
phages and T lymphocytes during granulomatous
responses. A number of data suggest that interferon
gamma (IFN-γ) and cytokines such as TNF-α, IL-12 and
IL-18 play a critical role in the formation of granuloma-
tous lesions [15]. Pathological similarities between sar-
coidosis and tuberculosis have led for a long time to the
suggestion that mycobacteria are the cause of sarcoidosis
[16]. However, the studies attempting to isolate mycobac-
teria in sarcoid tissues, even those using the most sensitivePage 2 of 8
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detect mycobacterial DNA. Propiniobacterium acnes has
also been incriminated as a causative agent but its role has
not yet been ascertained. Finally, it has been shown that
the incidence of sarcoidosis is influenced by genetic sus-
ceptibilities and particularly by polymorphisms involving
immunity [17]. It seems very probable that genetic factors
have also an important effect on disease presentation,
progression and overall prognosis [3,17].
No cause of sarcoidosis has yet been comfirmed, despite
numerous searches using most emerging diagnostic tools.
Several reasons could explain the difficulty to determine
an etiology in such a context [16]. First, sarcoidosis may
well not be a unique disease with a unique cause. Second,
the causal agent may be a yet unidentified microorganism.
Last, the mechanism underlying sarcoidosis may result
not only from a single organism or antigen but also be
related to the presence of adjuvant factors.
Clinical presentation
The presentation of sarcoidosis depends on epidemiolog-
ical factors such as age, sex and race, the duration of the
disease and the sites of involvement. Asymptomatic pres-
entations, erythema nodosum and hypercalcemia are
more frequent in Europeans, while symptomatic and mul-
tivisceral presentations are more frequent in Afro-Ameri-
cans [1-4,9]. Overall, sarcoidosis is mostly revealed in the
following circumstances: (i) respiratory symptoms, firstly
persistant dry cough in around 30% cases, (ii) extratho-
racic localizations, mainly peripheral lymph nodes, eyes
or skin, (iii) constitutional symptoms such as fatigue
(27%), weight loss (28%), fever (10–17%) or night
sweats and (iv) erythema nodosum (3–44%) [1,3,4,18].
Erythema nodosum is usually associated with bilateral
intrathoracic lymphadenopathies defining "Löfgren's syn-
drome" which is a benign form of the disease. Constitu-
tional symptoms, particularly asthenia, are often present
and can be a disabling problem [18]. Finally, an inciden-
tal discovery of sarcoidosis in asymptomatic patients with
chest X-ray aberrations is not uncommon (8–60%) [19].
Intrathoracic manifestations
Detailed occupational and environmental history is usu-
ally unremarkable and exposure to beryllium dusts and to
drugs inducing granulomatosis must be excluded. As a
general rule, no abnormality is audible at chest physical
examination. By contrast, chest X-ray is abnormal at some
point in 86–92% of cases and remains a key investigation
for diagnosis [1,2,9,19,20]. Radiographic staging of sar-
coidosis is based on the presence of lymphadenopathies
and lung infiltration without or with fibrosis [3]. Lym-
phadenopathies are typically hilar, bilateral, symmetrical
and non compressive, and often associated with right par-
atracheal and aortic-pulmonic window lymph node
involvement [19,20]. Lung infiltration is usually bilateral,
symmetrical and diffuse but with a patent predominance
for central regions and upper lobes. The pattern of infiltra-
tion is typically micronodular (diffuse punctiform opaci-
ties).
Stage I, the most frequent presentation, is defined as iso-
lated intrathoracic lymphadenopathy, stage II as lym-
phadenopathy accompanied by lung infiltration and stage
III as lone parenchymal infiltration. Stage IV refers to overt
lung fibrosis. Typical stage I and II are highly reliable for
diagnosing sarcoidosis, while stage III and IV are far less
accurate [3]. This classification was established more than
four decades ago but it still represents a major determi-
nant of prognosis [19]. The probability of further sponta-
neous healing decreases as a function of initial
radiographic stage (55–90% in stage I; 40–70% in stage II;
10–20% in stage III and 0% in stage IV) [3].
Pulmonary function tests typically demonstrate decreased
volumes and CO diffusing capacity with functional alter-
ation tending to be more frequent and marked from stage
I to stage IV [20]. Using the criterion of forced expiratory
volume in 1 sec (FEV1)/vital capacity (VC) ratio < 70%,
airway obstruction is encountered in 5.7% of cases [21].
Airway obstruction has been recognized as a marker of
poor prognosis including increased morbidity, higher fre-
quency of respiratory symptoms and radiographic stage IV
[22,23].
Fiberoptic bronchoscopy yields granulomas by means of
mucosal or transbronchial biopsy in 57–88% of cases
[3,24,25]. Lymphocytosis in broncho-alveolar lavage
(BAL) is observed in 90% of cases and a CD4+/CD8+ T
lymphocyte ratio greater than 3.5 in half cases [24]. Trans-
bronchial needle aspiration makes also possible valuable
samplings of hilar and mediastinal lymph nodes [25].
Chest high resolution computed tomography (HRCT) has
a better diagnosis accuracy than chest X-ray [19,20]. The
hallmark of pulmonary sarcoidosis are widespread micro-
nodules with a typical perilymphangitic distribution and
a predominance for the middle and upper parts of the
lungs. However, HRCT is not always necessary when a
confident diagnosis can be made from typical clinical and
radiographic features. By contrast, HRCT makes compel-
ling diagnostic contributions in tricky cases and in detect-
ing complications of the lung disease. HRCT is also
particularly useful in cases difficult to treat [26].
Extrathoracic manifestations
Apart from intrathoracic lymph nodes and lung, the most
frequent sites of sarcoidosis involvement include periph-
eral lymph nodes, eyes, skin and liver, each being noted in
about 10–25% of cases in most series [1-4,9]. VirtuallyPage 3 of 8
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quency and degree of impairement is variable according
to localizations. Overall, extrathoracic manifestations
occur in about half of the cases and in this setting are asso-
ciated with intrathoracic involvement in 80–90% cases.
Extrathoracic localizations can be confined to one organ
or be multiple and diversely combined.
Peripheral lymphadenopathies are easily palpable and
their frequency varies between series up to 70%. They are
asymptomatic, firm, of various size and every site of
lymph nodes may be affected. Peripheral lymphadenopa-
thies are readily accessible to biopsy. They can be local-
ized in the abdomen where they are recognizable by
abdominal echography, computed tomography (CT) or
magnetic resonance imaging (MRI) and they can be asso-
ciated with liver or splenic nodules or enlargement.
The frequency of ocular sarcoidosis is comprised
between 10 and 50% according to published studies. This
wide range is due to recruitment bias in series reported by
ophtalmologists and to epidemiological factors with an
increased incidence in Japanese patients [27]. Any part of
the eye may be involved in sarcoidosis. Macroscopic nod-
ules of the conjunctiva are seen in 6–40% of cases and
allow evidence of granulomas in 67% of cases [27]. Ante-
rior uveitis can be an initial, acute and symptomatic (red
eyes, photophobia and blurred vision) manifestation but
it can also be asymptomatic and have a chronic course jus-
tifying a systematic eye investigation including a slit lamp
examination. Similarly, intermediate uveitis can be symp-
tomatic or not. Posterior uveitis is encountered in up to
28% of cases with eye sarcoidosis and it may be associated
with neurologic involvement. Optic neuropathy is very
rare but it may provoke a rapid and definitive loss of
vision in the absence of immediate and adequate systemic
treatment. Lacrimal involvement may lead to sicca kerato-
conjonctivitis, while bilateral enlargement of lacrimal
gland is unfrequent.
Skin manifestations of sarcoidosis are heterogeneous.
Erythema nodosum is a non specific association of sar-
coidosis realizing typically Löfgren's syndrome in the
presence of bilateral hilar lymphadenopathy. The inci-
dence of Löfgren's syndrome varies according to epidemi-
ological factors (see "Epidemiology"). The frequency of
specific skin manifestations of sarcoidosis ranges from 10
to 40% cases [28]. They appear at any stage of the disease
and can remain strictly isolated in one third of cases [28].
The clinical picture of skin sarcoidosis is variegated: mac-
ulopapular lesions of various size, changes of old scars,
lupus pernio, plaque formation, subcutaneous lesions etc.
Skin lesions supply a plain and proper site for biopsy with
the exception of erythema nodosum. Lesions of the face
such as lupus pernio are very unpleasant and often linked
with a longstanding evolution of sarcoidosis and osseous
and sinonasal localizations. They are often difficult to
control with treatments.
Liver involvement
while granulomas are found in up to 60–80% of liver
biopsy specimens, abnormalities of biological tests, pri-
marily cholestasis, are evidenced in only about 20% of
cases. Clinical enlargement of the liver is far less frequent.
Chronic intrahepatic cholestasis, hepatic dysfunction, cir-
rhosis and portal hypertension are all severe but rare com-
plications of sarcoidosis.
Localizations of sarcoidosis in heart, central nervous sys-
tem, larynx or kidney are less frequent but potentially seri-
ous.
Cardiac involvement of sarcoidosis appears to be much
more frequent in Japanese population, particularly in
females > 50 years, than in Europeans and Americans in
which it concerns approximatively 5% of cases [29,30]. It
can occur at any point of time during the course of sar-
coidosis. The left ventricular myocardium and, more spe-
cifically, the interventricular septum and the free left
lateral wall are the most frequently involved structures in
sarcoidosis. Main relevant signs include atrio-ventricular
block, complete right bundle branch block (which is nota-
bly frequent and suggestive), ventricular hyperexcitability,
ventricular tachycardia, left ventricular dysfunction and
sudden death. The diagnosis of cardiac sarcoidosis is often
a challenging issue for physicians. Serial electrocardio-
gram (ECG) during evolution survey, echocardiography,
24-h Holter monitoring of ECG, Thallium scan, MRI and
and 18FDG PET can be helpful tools for diagnosis (29,30).
Endomyocardial biopsy is theoretically the most confi-
dent mean to ascertain the diagnosis but in clinical prac-
tice it lacks sensitivity and it is an invasive procedure,
which constitutes major limitations. Thus, the diagnosis
of cardiac sarcoidosis usually relies on the conjunction of
multiple arguments: (i) evidence of sarcoidosis, (ii) pres-
ence of cardiac abnormalities compatible with cardiac sar-
coidosis and (iii) exclusion of any other cause of cardiac
disease.
Any part of the nervous system can be involved in sar-
coidosis with a frequency around 10% [31,32]: meninges,
central nervous system, cranial nerves and peripheral
nerves. Aseptic meningitis can cause symptoms such as
fever or headache and be associated with central nervous
system manifestations or cranial neuropathy but can also
be asymptomatic. Central nervous system manifestations
are most frequent in Caucasians. Various clinical expres-
sion can be observed: neuro-endocrine symptoms, psychi-
atric symptoms, seizures, cognitive abnormalities,
hydrocephalia, spinal cord impairment and various neu-Page 4 of 8
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sensitive tests to diagnose central nervous system sar-
coidosis and guide therapeutical management. Cranial
neuropathies prevale in Black patients. Although all cra-
nial nerves can be concerned, seventh nerve palsy is the
most common sign followed by optic neuropathy and
involvement of the eighth and fifth nerves. Heerfordt's
syndrome which associates uveitis, parotid gland enlarge-
ment, fever and cranial neuropathy, usually seventh nerve
palsy, is highly suggestive of sarcoidosis. The diagnosis of
neurosarcoidosis relies on the conjunction of: (i) con-
firmed sarcoidosis, (ii) neurologic involvement compati-
ble with neurosarcoidosis and (iii) exclusion of an
alternative neurologic disorder.
Clinically significant involvement of kidneys is extremely
rare, cited in 0.7% of cases [9,33]. Histology typically
reveals granulomatous interstitial nephritis. Biology
shows decreased creatinine clearance and low or absent
proteinuria. Sarcoidosis can also produce urinary lithiasis
and nephrocalcinosis while the relations between diverse
forms of glomerulonephritis which are very uncommon
and sarcoidoisis are very unclear.
Parotid enlargement is seen in 5–10% of cases. Sarcoido-
sis of the upper respiratory tract occurrs in 0.7 and 6 %
and may assume various features in relation to the
involvement of sinonasal mucosa, pharynx and larynx.
Laryngeal sarcoidosis is potentially serious by provoking
airway obstruction. Sinonasal sarcoidosis is well-recog-
nised to be a chronic and recalcitrant form of the disease,
which is associated with lupus pernio in half cases
[34,35]. Typically, patients complain of chronic crusting
rhinitis but sinonasal involvement can occasionally lead
to bone lysis and eventually disfiguiring saddle nose [35].
Articular involvement may be acute and transient or
chronic and persistent [36]. Yet, whilst joint pains occur
in 25–39% of patients with sarcoidosis, deforming arthri-
tis is rare. Osseous involvement is associated with charac-
teristic abnormalities on radiography [36]. Sarcoidosis
usually affects small joints of the hands and feet, knees,
ankles, elbows and wrists. Sympomatic muscle involve-
ment is particularly unfrequent (1.4–2.3% cases). Gas-
trointestinal tract is involved in less than 1.0%. The
stomach is the most commonly involved part of gastron-
intestinal tract, sometimes diagnosed incidentally [37].
Sarcoidosis of the small intestine and colon is much rarer
and may mimic Crohn's disease. Pancreas and peritoneal
localizations are exceptional. Splenic enlargement is
observed in 5–10%, it is usually minimal and asympto-
matic and causes rarely decrease in the count of platelets,
red and white cells [37]. In the absence of splenomegaly,
hematological alterations may be exceptionally due to a
granulomatous infiltration of the bone marrow or to an
autoimmune process, mainly hemolytic anemia or
thrombopenia [37]. However, the most frequent abnor-
mality is lymphopenia, which mechanism is a redistribu-
tion of blood T cells to sites of disease.
Biologic manifestations
Hypercalcemia is present in around 11% and hypercalciu-
ria in around 36% of cases [33]. Serum angiotensin con-
verting enzyme (SACE) is believed to reflect disease
activity and dissemination but it is increased in about
60% of cases [24]. Serum protein electrophoresis shows
polyclonal hypergammaglobulinemia in half cases.
Hypogammaglobulinemia must prompt clinicians to seek
alternative diagnosis to sarcoidosis, mainly variable com-
mon immunodeficiency and lymphoma. Routine blood
tests are useful to evidence abnormal hepatic function and
more rarely increased creatinine, and hematologic abnor-
malities, as discussed above.
Special situations
Sarcoidosis and pregnancy
Sarcoidosis does not influence pregnancy adversely.
Whether or not the disease improves during pregnancy
remains debated. On the other hand, it is clear that sar-
coidosis may exacerbate again in the puerperium, which
justifies a close surveillance within a period of 6 months
after delivery. Pregancy should be avoided when treat-
ments other than corticosteroids are necessary because of
potential foetal toxicity or teratogenicity [37]. It is also
contra-indicated in case of severe visceral involvement,
particularly advanced respiratory insufficiency.
Sarcoidosis in children
Sarcoidosis is rare before the age of 15 and exceptional
before 4. The disease of chidren resembles that of adults
with respect to the distribution of organs involved. In old
literature, sarcoidosis with an onset in children under the
age of 4 has been reported to have an original presenta-
tion characterized by the combination of polyarthritis,
uveitis and skin rash, and the rarity of intrathoracic
involvement. It is likely that most of reported cases had
actually Blau syndrome.
Association of sarcoidosis with other conditions
Co-existence of sarcoidosis with diverse autoimmune
conditions, other granulomatosis and proliferations in
the same individual is classical, even though still contro-
versial. These include all connective tissue diseases but
principally scleroderma and Sjogren's syndrome, as well
as ankylosing spondilitis, primary biliary cirrhosis and
auto-immune disorders of the thyroid [37]. Interestingly,
an association with Crohn's disease, another granuloma-
tous disease of unknown cause, has been reported [37].
Finally, association of lymphoproliferative and solid
malignancies must be kept in mind and can raise difficult
diagnosis problems.Page 5 of 8
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The diagnosis of sarcoidosis relies on clinico-radiographi-
cal presentation and evidence of non caseating granulo-
mas on biopsy specimens after appropriate exclusion of
other granulomatous disorders [3,24]. Diagnosis may
benefit from the amalgamation of other supporting argu-
ments such as typical findings on HRCT, CD4/CD8 T lym-
phocyte ratio higher than 3.5 in BAL, SACE level twice
higher than the upper normal limit or typical abnormal
calcium metabolism.
Most recommended sites to obtain a histological confir-
mation are mucosal or transbronchial biopsy through
fiberoptic bronchoscopy [3,24], skin lesions, peripheral
lymphadenopathy, conjonctival nodules or lip biopsy of
accessory salivary glands. Sampling hilar or mediastinal
lymph nodes through transbronchial needle aspiration or
mediastinoscopy may be required [3,24,25]. Videothora-
coscopic lung biopsy may rarely be necessary, while other
sites can be guided by clinical findings. The diagnostic
yield of all these procedures is more than 90% [3]. Some
very typical cases like Löfgren's syndrome may obviate an
immediate invasive biopsy procedure but histologic con-
firmation is mandatory in difficult cases or before treat-
ment initiation.
Gallium-67-citrate (67Ga) scintigraphy has long been used
as a diagnostic tool in sarcoidosis [38] but is only rarely
done now. Uptakes of 67Ga is seen in intrathoracic and
various extrathoracic localizations of the disease. The cur-
rent indications of 67Ga scintigraphy are as follows: (i) to
substantiate the diagnosis in difficult cases, particularly in
those with normal chest-X ray and a suspicion of sarcoido-
sis, when the "lambda plus panda" patterns is found,
which is almost pathognomonic of the disease, (ii) to
identify other clinically silent extra-pulmonary uptakes
and provide potential sites for biopsies, (iii) and to assess
activity in difficult cases such as stage IV disease in which
whether or not to initiate potentially toxic therapy is a
dilemma. Recently, an increasing literature on 18F-fluoro-
2-deoxyglucose positron emission tomography (18FDG
PET) in sarcoidosis has been published, but its role
remains to be delineated [38]. Moreover, one should bear
in mind the high level of radiation dose delivered by these
isotopic investigations.
Differential diagnosis
Other granulomatous diseases need to be ruled out before
the diagnosis of sarcoidosis is ascertained [3,24]. In
almost all cases, clinical history, epidemiology with an
appropriate investigation of exposure to infections such as
tuberculosis or to beryllium inhalation, together with a
proper evaluation of all tests are sufficient to discriminate
between sarcoidosis and other granulomatous disorders.
Tuberculosis, some fungal infections, chronic beryllium
disease, granulomatous disorder induced by interferon α
and β or intravesical BCG therapy or associated with com-
mon variable immunodeficiency are those conditions
which can best mimic sarcoidosis. In infants under four
years old, the Blau syndrome has to be considered before
sarcoidosis, specially in the absence of thoracic involve-
ment. Loco-regional granulomatous reactions satellite of
breast or lung carcinoma and of lymphomas are rarely dif-
ficult to differenciate from sarcoidosis as well as other
granulomatous disorders of unknown cause like Crohn's
disease or Wegener granulomatosis.
Prognosis and evolution
Sarcoidosis is generally a time-limited disease that lasts
for 12–36 months in half cases, for less than 5 years in
most remaining cases and occasionnally for multiple dec-
ades [3]. Serial assessments are warranted until disease
recovery in order to appreciate individual evolution. A
minimum delay of three years is necessary after discontin-
uation of therapy before healing can be established [3].
The most valid prognostic factors remain the mode of
onset, the disease extent and chest-X ray staging. An acute
onset with Löfgren's syndrome or asymptomatic bilateral
hilar lymphadenopathy usually confers a self-limiting
course [1-4]. On the other hand, Black race, age of onset >
40 years, lupus pernio, chronic uveitis, sinonasal or
osseous localizations, central nervous system or cardiac
involvement, chronic hypercalcemia, nephrocalcinosis
and stage III and IV are linked to more severe long-stand-
ing evolution [3,20,34,35]. Procedures aimed to stage dis-
ease activity, particularly gallium scanning and BAL, have
been proved to be disappointing in prognosis assessment.
The most severe and frequent complication of sarcoidosis
is the occurrence of pulmonary fibrosis. This is usually
associated with chronic dyspnea and frank impairment of
pulmonary function. Pulmonary fibrosis is the most fre-
quent cause of respiratory failure and results in the major-
ity of deaths related to sarcoidosis in western countries.
Pulmonary fibrosis is the consequence of chronic unre-
mitting granulomatous process in the lung. The concern
about the development of pulmonary fibrosis is the rea-
son for treating cases of sarcoidosis with persistant pul-
monary infiltration.
Airway obstruction can be due to several mechanisms in
sarcoidosis: bronchial distortion secondary to pulmonary
fibrosis, direct localization of granulomas in the airways,
or more seldom extrinsic bronchial compression by hilar
or mediastinal lymphadenopathy.
Pulmonary hypertension, i.e. increased pulmonary arte-
rial pressure usually occurs in end-stage fibrotic cases. The
severity of pulmonary hypertension is often out of pro-Page 6 of 8
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implies the role of alternative mechanisms including spe-
cific involvement of small lung vessels by sarcoidosis [39].
Pulmonary hypertension is a strong predictive indicator
of mortality.
Mycetoma formation is a recognized complication of
advanced pulmonary fibrosis and it is believed to be asso-
ciated with an increased risk of death because of severe
bleeding or underlying respiratory insufficiency.
Some other severe localizations may also punctuate the
evolution of sarcoidosis. In cardiac sarcoidosis, episodes
of sustained ventricular tachycardia coupled with left ven-
tricular dilatation are associated with an increased risk of
death [40]. Central nervous system sarcoidosis may repre-
sent the third cause of death after lung and cardiac local-
izions. Various other conditions, even though non lethal,
can be associated with important discomfort and disabil-
ity: disgracious skin manifestations, particularly lupus
pernio, sinonasal and laryngeal localizations, renal mani-
festations and severe ocular localizations. Overall, 10–
20% of sarcoidosis patients suffer from permanent seque-
lae [3]. Treatments which are often given for long periods
of time are frequently the source of various troublesome
adverse effects. This is particularly the case with corticos-
teroids that may be responsible for overweight, systemic
arterial hypertension, diabetes mellitus, myopathy, buf-
falo neck etc.
Treatment
The appropriate therapy for sarcoidosis has not yet been
well defined for all patients [3,7,9]. Between 30 and 70%
of patients never require therapy. In the other cases, a
treatment, often corticosteroids, is necessary, either at the
onset of the disease or during follow-up because of vari-
ous consequences.
Cardiac, neurological, renal, ocular sarcoidosis not
responding to topical therapy and malignant hypercal-
cemia always necessitate systemic therapy. Incapacitating
general symptoms may lead to short-course corticosteroid
therapy [1-4,7,8]. For pulmonary disease, systemic ther-
apy is recommended in patients with stage II or III who
are symptomatic or who disclose significant deterioration
in serial pulmonary function tests and/or chest X-ray.
Treatment is clearly not indicated in asymptomatic stage
I. In Löfgren syndrome, erythema nodosum justifies non-
steroidal anti-inflammatory drugs or colchicine for some
weeks (but rarely corticosteroids) taking into account the
usually good prognosis in this setting. Stage IV with
advanced pulmonary fibrosis is usually poorly or not at all
affected by systemic therapy. However, a trial of therapy to
identify residual inflammation is warranted particularly
in patients with persistent signs of activity. For pulmonary
sarcoidosis, protocols suggest the initial dose of 20 to 40
mg daily of prednisone or its equivalent on alternate days.
Higher dosage may be necessary to control cardiac, neuro-
logic, renal, ophtalmologic and laryngeal involvement.
After 4 weeks to 3 months therapy, posology is tapered.
Therapy must be maintained for at least 12 months [3].
Some patients experience repeated relapses and may
require long-term low-dose therapy during years.
Antimalarial drugs are a treatment of choice for mild iso-
lated cutaneous lesions [3,8]. Aminoquinolins are also
helpful for hypercalcemia. Methotrexate has been the
most extensively used among cytotoxics. Methotrexate is
effective in pulmonary and most extra-pulmonary manis-
festations, particularly skin, ophthalmic, nervous system
and musculoskeletal localizations [8]. Methotrexate-
induced hepatotoxicity occurs in about 10% of patients
with sarcoidosis treated for more than two years. Azathio-
prine has clearly proved benefit as a corticosteroid sparing
agent. Cyclophosphamide has been occasionally offered
in refractory disease with interesting results in cortico-
resistant cardiac and neurologic sarcoidosis. Thalidomide
has demonstrated efficacy for lupus pernio unresponsive
to prior therapy. However, its effect on pulmonary disease
is unclear. Moreover, the side-effects of thalidomide can
be extremely serious. TNF-α inhibitors have led to a dra-
matic improvement in small series or several case reports
with refractory lupus pernio, uveitis or central nervous
system localization. Recently, a double-blind study dem-
onstrated a short-timed efficiency of infliximab in severe
pulmonary localizations [41]. Yet, etanercept seems less
promising as shown in a prospective open-label phase-2
trial. Controlled studies are needed to clearly identify the
patients who may profit from these novel therapies.
Currently available agents for the prevention of glucocor-
ticoid-induced osteoporosis may not be safe in sarcoido-
sis. Vitamin D should be avoided. Calcium
supplementation may be given to patients without hyper-
calciuria under periodic survey of calcium metabolism.
Bisphosphonates are also efficient in this setting.
Symptomatic treatments and recommendations may be
given in sarcoidosis: low calcium diet and avoidance of
sunlight exposure, supplemental oxygen, cardiac drugs,
implantable pacemakers or cardiovertible-defibrillator,
hormonal substitution, anti-epileptic agents.
Lung, liver and heart transplantation have been success-
fully performed in patients with end-stage refractory sar-
coidosis [42]. Medical therapy must have been exhausted
before candidates are selected for transplantation.Page 7 of 8
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